UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Leukemia, 2015-10, Vol.29 (10), p.2039-2049

2015

Volltextzugriff (PDF)

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis

Bone marrow transplantation (Basingstoke), 2015-11, Vol.50 (11), p.1424-1431

2015

Volltextzugriff (PDF)

Case report: persistently seronegative neuroborreliosis in an immunocompromised patient

BMC infectious diseases, 2018-08, Vol.18 (1), p.362-362, Article 362

2018

Volltextzugriff (PDF)

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

Bone marrow transplantation (Basingstoke), 2017-10, Vol.52 (10), p.1378-1383

2017

Volltextzugriff (PDF)

Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab

Supportive care in cancer, 2024-01, Vol.32 (1), p.20-20, Article 20

2024

Volltextzugriff (PDF)

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma

Bone marrow transplantation (Basingstoke), 2006-06, Vol.37 (12), p.1135-1141

2006

Volltextzugriff (PDF)

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

Leukemia, 2012-02, Vol.26 (2), p.199-213

2012

Volltextzugriff (PDF)

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

European journal of haematology, 2024-03, Vol.112 (3), p.360-366

2024

Volltextzugriff (PDF)

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

International journal of laboratory hematology, 2016-05, Vol.38 (S1), p.110-122

2016

Volltextzugriff (PDF)

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs

Bone marrow transplantation (Basingstoke), 2015-06, Vol.50 (6), p.822-828

2015

Volltextzugriff (PDF)

Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome

Bone marrow transplantation (Basingstoke), 2008-05, Vol.41 (9), p.779-784

2008

Volltextzugriff (PDF)

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

Leukemia, 2004-06, Vol.18 (6), p.1078-1084

2004

Volltextzugriff (PDF)

Growth factors and antiapoptotic signaling pathways in multiple myeloma

Leukemia, 2005-12, Vol.19 (12), p.2177-2185

2005

Volltextzugriff (PDF)

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial

European journal of cancer (1990), 2024-08, Vol.207, p.114153, Article 114153

2024

Volltextzugriff (PDF)

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

Haematologica (Roma), 2014-06, Vol.99 (6), p.984

2014

Volltextzugriff (PDF)

Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options

Netherlands journal of medicine, 2019-09, Vol.77 (7), p.243-254

2019

Volltextzugriff (PDF)

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

The New England journal of medicine, 2015-09, Vol.373 (13), p.1207-1219

2015

Volltextzugriff (PDF)

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

Leukemia, 2002-07, Vol.16 (7), p.1362-1371

2002

Volltextzugriff (PDF)

Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience

Bone marrow transplantation (Basingstoke), 2011-02, Vol.46 (2), p.244-249

2011

Volltextzugriff (PDF)

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL

HemaSphere, 2022-06, Vol.6 (Suppl), p.758-759

2022

Volltextzugriff (PDF)

P1739: HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN‐LABEL DOSE ESCALATION STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.1620-1621

2022

Volltextzugriff (PDF)

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY

HemaSphere, 2022-06, Vol.6 (Suppl), p.825-826

2022

Volltextzugriff (PDF)

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING‐ADJUSTED INDIRECT TREATMENT COMPARISON

HemaSphere, 2022-06, Vol.6 (Suppl), p.789-790

2022

Volltextzugriff (PDF)

PB2014: TECLISTAMAB VS SELINEXOR‐DEXAMETHASONE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING‐ADJUSTED INDIRECT COMPARISON

HemaSphere, 2022-06, Vol.6 (Suppl), p.1885-1886

2022

Volltextzugriff (PDF)

New developments in the treatment of patients with multiple myeloma

Netherlands journal of medicine, 2010, Vol.68 (1), p.24-32

2010

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(79)

Publikationsform

Sprache

Englisch
(90)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(57)
Humans
(45)
Hematology
(35)
Multiple Myeloma
(27)
Male
(22)
Oncology
(21)
Aged
(19)
Female
(19)
Middle Aged
(19)
Adult
(16)
Biological And Medical Sciences
(16)
Multiple Myeloma - Drug Therapy
(16)
Patients
(15)
Medical Sciences
(14)
Immunotherapy
(11)
Multiple Myeloma - Pathology
(11)
Multiple Myeloma - Therapy
(11)
Immunodeficiencies. Immunoglobulinopathies
(10)
Immunoglobulinopathies
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis

Case report: persistently seronegative neuroborreliosis in an immunocompromised patient

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs

Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

Growth factors and antiapoptotic signaling pathways in multiple myeloma

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network

Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience

P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL

P1739: HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN‐LABEL DOSE ESCALATION STUDY

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING‐ADJUSTED INDIRECT TREATMENT COMPARISON

PB2014: TECLISTAMAB VS SELINEXOR‐DEXAMETHASONE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING‐ADJUSTED INDIRECT COMPARISON

New developments in the treatment of patients with multiple myeloma

Suchergebnisse filtern